:: Volume 21, Issue 2 (4-2023) ::
Int J Radiat Res 2023, 21(2): 211-215 Back to browse issues page
18F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting prognosis of small cell lung cancer patients
X. Chen , L. Shen , Y. Hong
Department of Anorectal Surgery, The First People’s Hospital of Xiaoshan District, 311200, Hangzhou, Zhejiang, P.R. China , hyp139640@126.com
Abstract:   (759 Views)
Background: The purpose of this study is to evaluate the accuracy of 18F-fluorodeoxyglucose (FDG) positron emission tomography/Computed Tomography (PET/CT) in predicting tumor prognosis in patients with Small Cell Lung Cancer (SCLC). Materials and Methods: From July 2015 to March 2019, all 30 SCLC patients who had analyzable PET/CTs and adequate clinical data were evaluated. Medical records were retrospectively reviewed, including age, gender, stage, performance status according to the Eastern Cooperative Oncology Group (ECOG), metabolic parameters on PET and treatment programs. Factors potentially affecting tumor prognosis were examined by models of univariate and multivariate Cox proportional hazards regression. Results: The median age of the cohort was 58 years (range: 39-93). A median follow-up period of 12 months was observed. Multivariate Cox proportional hazards regression demonstrated that the overall survival (OS) (p = 0.03) and progression-free survival (PFS) (p = 0.014) were related only to the metabolic tumor volume (MTV). The optimal cutoff threshold was 98 mm3, and the receiver operating characteristic (ROC) curve had an area under it of 0.75. In comparison to the high-MTV group, the low-MTV group had statistically substantially prolonged OS (p = 0.004) and PFS (p < 0.001). Conclusion: The MTV of 18F-FDG PET/CT is a major independent prognostic factor in SCLC patients and has significant implications for OS and PSF.
Keywords: Positron emission, computed tomography, lung cancer patients.
Full-Text [PDF 617 kb]   (565 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
1. 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin, 65(2): 87-108. [DOI:10.3322/caac.21262] [PMID]
2. Hu Z, Li M, Chen Z, Zhan C, Lin Z, Wang Q (2019) Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018. Transl Lung Cancer Res, 8(6): 1091-1106. [DOI:10.21037/tlcr.2019.10.17] [PMID] []
3. Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, et al. (2016) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 11(3): 300-311. [DOI:10.1016/j.jtho.2015.10.008] [PMID]
4. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, et al. (2007) The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol, 2(12): 1067-1077. [DOI:10.1097/JTO.0b013e31815bdc0d] [PMID]
5. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol, 3(5): 457-466. [DOI:10.1097/JTO.0b013e31816de2b8] [PMID]
6. Wang Y, Zou S, Zhao Z, Liu P, Ke C, Xu S (2020) New insights into small-cell lung cancer development and therapy. Cell Biol Int, 44(8): 1564-1576. [DOI:10.1002/cbin.11359] [PMID] []
7. Li X, Enzerra M, Smith DA, Rahnemai-Azar AA, et al. (2019) Lesser Known Facts of Small Cell Lung Cancer. J Comput Assist Tomogr, 43(4): 584-591. [DOI:10.1097/RCT.0000000000000847] [PMID]
8. Turrisi AT 3rd, Kim K, Blum R, Sause WT, et al. (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 340 (4): 265-271. [DOI:10.1056/NEJM199901283400403] [PMID]
9. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. (2005) [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol, 23(6): 1136-1143. [DOI:10.1200/JCO.2005.06.129] [PMID]
10. Davies A, Tan C, Paschalides C, Barrington SF, et al. (2007) FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer, 55(1): 75-78. [DOI:10.1016/j.lungcan.2006.09.010] [PMID]
11. Guo H, Zhu H, Xi Y, Zhang B, Li L, Huang Y, et al. (2007) Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med, 48(8): 1251-1258. [DOI:10.2967/jnumed.106.036509] [PMID]
12. Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, et al. (2009) High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res, 15(7): 2426-2432. [DOI:10.1158/1078-0432.CCR-08-2258] [PMID]
13. Roedl JB, Halpern EF, Colen RR, Sahani DV, et al. (2009) Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol, 11(1): 54-60. [DOI:10.1007/s11307-008-0169-9] [PMID]
14. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. (2009) Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys, 74(5):1335-1341. [DOI:10.1016/j.ijrobp.2008.10.060] [PMID] []
15. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. (2010) Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol, 17(1): 115-122. [DOI:10.1245/s10434-009-0719-7] [PMID]
16. Um SW, Kim H, Koh WJ, Suh GY, Chung MP, Kwon OJ, et al. (2009) Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol, 4(11): 1331-1336. [DOI:10.1097/JTO.0b013e3181b6be3e] [PMID]
17. Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. (2012) Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging, 39(6): 925-935. [DOI:10.1007/s00259-011-2059-7] [PMID]
18. Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med, 48(6): 932-945. [DOI:10.2967/jnumed.106.035774] [PMID]
19. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, et al. (2012) Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer, 13(1): 52-58. [DOI:10.1016/j.cllc.2011.05.001] [PMID] []
20. Lee P, Weerasuriya DK, Lavori PW, Quon A, et al. (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys, 69(2): 328-333. [DOI:10.1016/j.ijrobp.2007.04.036] [PMID]
21. Ball DL, Fisher R, Burmeister B, Graham P, et al. (2006) Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol, 1(7): 667-672. https://doi.org/10.1097/01243894-200609000-00011 [DOI:10.1016/S1556-0864(15)30379-8]

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 2 (4-2023) Back to browse issues page